Four studies captured the thoughts of healthcare practitioners/clinical experts about prescribing GLP‐1 RAs in the context of T2DM [24, 27, 28, 38], one specifically in patients with chronic kidney disease [28]. The gene discussed is GLP1R; the disease is chronic kidney disease.